Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB - LARVOL DELTA

TRAJECTORY OF SERUM CALCIUM CONCENTRATION AND FACTORS ASSOCIATED WITH HYPOCALCEMIA IN MAINTENANCE DIALYSIS PATIENTS ON OSTEOPOROSIS MEDICATIONS (ISN-WCN 2026) - "New users of osteoporosis medications were defined as patients with claims records for bisphosphonates, denosumab, romosozumab, or parathyroid hormone (PTH) analogs, with a 6-month lookback period to ensure new use. Pre-existing hyperparathyroidism emerged as a key risk factor, suggesting that PTH management should be optimized before initiating these medications. Enhanced calcium monitoring is essential when prescribing these agents to dialysis patients."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Orthopedics • Osteoporosis • Rheumatology

Response to the letter to the editor regarding "treatment with romosozumab in patients with osteoporosis on maintenance hemodialysis". (PubMed, J Bone Miner Metab) - No abstract available

Journal • Osteoporosis • Rheumatology

Should Romosozumab be used in advanced CKD? (ERA 2026) - No abstract available

Metastases • Chronic Kidney Disease

Mapping a Decade of Osteoporosis and Fracture Research: A Bibliometric Analysis (2015-2025). (PubMed, J Bone Metab) - "Global osteoporosis research demonstrates sustained productivity but declining collaboration and limited thematic diversification. Strengthening international networks, supporting underrepresented regions, and expanding focus to preventive and non-pharmacological strategies are essential for equitable and impactful progress."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Decoding Chronic Charcot Arthropathy: Molecular Mechanisms, Predictive Biomarkers, and Emerging Therapies. (PubMed, JB JS Open Access) - "» Current management relies primarily on mechanical interventions (accommodative footwear, bracing, surgical reconstruction for unbraceable deformities), but emerging molecular therapies targeting RANKL (denosumab), pro-inflammatory cytokines (IL-17 inhibitors), and Wnt pathway (romosozumab) show promise for disease modification. » Integrated risk stratification models combining genetic risk scores, serum biomarkers (RANKL/OPG ratio, vitamin D levels), and clinical factors can identify high-risk individuals (AUC 0.89), enabling targeted preventive interventions including vitamin D supplementation, prophylactic off-loading, and potentially pharmacological prevention."

Biomarker • Journal • Review • Diabetic Neuropathy • Infectious Disease • Inflammation • Metabolic Disorders • Pain • Rheumatology • IL17A • TNFRSF11B

Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations. (PubMed, Drugs Aging) - "Careful consideration must be given to the selection of antidiabetic medications, avoiding agents known to harm bone (e.g., thiazolidinediones) and preferring those with neutral or potentially beneficial skeletal effects (e.g., metformin, dipeptidyl peptidase-4 inhibitors [DPP-4i], glucagon-like peptide-1 receptor agonists [GLP-1 RAs]). Osteoporosis pharmacotherapies, including antiresorptive (bisphosphonates, denosumab) and anabolic agents (teriparatide, abaloparatide, romosozumab), appear effective in patients with diabetes largely on the basis of post hoc analyses and observational data, although evidence specific to this population remains limited. Integrating geriatric principles, such as assessing frailty and polypharmacy, is essential for optimizing care and improving outcomes for older adults with diabetes and bone fragility."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Mechanisms Underlying the Waning of Osteoanabolic Therapy Effects in Osteoporosis. (PubMed, J Bone Miner Res) - "Osteoanabolic therapies such as parathyroid hormone (PTH) analogs (teriparatide, abaloparatide) and the sclerostin inhibitor romosozumab rapidly stimulate new bone deposition but their bone-building effects are not indefinite...Finally, potential strategies to extend or rekindle anabolic effects are discussed - including sequential and combination therapies and adjunctive mechanical loading - with a view toward maximizing bone gains and reducing fracture risk. Understanding why anabolic drug efficacy attenuates provides insight into bone biology and guides the design of regimens to achieve more sustained increases in bone mass and strength."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • DKK1

Breakfast Product Theater: 12 Months to Stronger Bones for Your Postmenopausal Women at High Risk for Fracture Sponsored by Amgen Bone (AACE 2026) - "Sponsored by Amgen Bone Objectives: • Highlight that factors beyond BMD contribute to fracture risk, including the need to improve bone architecture & strength • Expand understanding how to identify risk factors that reclassifies a patient to be defined as VHFR in alignment with Guidelines and the ASBMR task force Content includes: • Assessing Fracture Risk• ASBMR/BHOF position statement• Bone architecture & strength• Dual mechanism of action• EVENITY® data: FRAME & ARCH"

Clinical • Musculoskeletal Diseases • Orthopedics

Romosozumab does not improve volumetric bone mineral density at distal radius but increases bone strength: a prospective study (EULAR 2026) - No abstract available

Clinical

Romosozumab versus denosumab in glucocorticoid-induced osteoporosis: an extended observation of a randomized controlled trial at 48 months (EULAR 2026) - No abstract available

Clinical • Osteoporosis • Rheumatology

Treatment with romosozumab in patients with osteoporosis on maintenance hemodialysis. (PubMed, J Bone Miner Metab) - No abstract available

Journal • Osteoporosis • Rheumatology

Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. (PubMed, Osteoporos Int) - "Thus, romosozumab might be a specific treatment for these patients. However, further studies are needed with larger patient cohorts and in particular with regard to biallelic loss-of-function variants in the LRP 5/6 or WNT1 gene."

Journal • Gene Therapies • Osteoporosis • Rheumatology

ATRIO (L4204): ATRIO Study:nEffect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporosis: A Phase IV, Low-Risk Intervention Study. (clinicaltrialsregister.eu) - P4 | N=60 | Not yet recruiting | Sponsor: Ospedale Galeazzi S.p.A.

New P4 trial • Atherosclerosis • Osteoporosis • Rheumatology

COMPARATIVE CARDIOVASCULAR RISK IN U.S. POSTMENOPAUSAL WOMEN STARTING ROMOSOZUMAB VS DENOSUMAB: A HIGH-DIMENSIONAL INVERSE PROBABILITY OF SELECTION WEIGHTING ANALYSIS FOR MISSING CARDIOVASCULAR RISK FACTORS (ISPOR 2026) - "The association between CV risk and initiating romo could be affected by the missingness of CV risk in complete-case analysis. Hd-IPSW could mitigate such bias. Future comparative safety studies should carefully evaluate CV risk in light of missingness patterns."

Clinical • Cardiovascular • Musculoskeletal Diseases • Rare Diseases

CLINICAL AND ECONOMIC BENEFITS OF EARLY ROMOSOZUMAB INITIATION IN PATIENTS WITH RECENT OSTEOPOROTIC HIP FRACTURES IN JAPAN (ISPOR 2026) - "The results of our study support that using romosozumab first in the therapeutic sequence, as per Japanese treatment guideline recommendations, is the cost-effective treatment (against delayed romosozumab, vitamin D3, alendronate) with favourable budget impact for patients aged ≥ 50 years with recent osteoporotic hip fractures in Japan."

Clinical • HEOR • Musculoskeletal Diseases • Orthopedics • Osteoporosis

Pediatric Safety Follow-up Study of Prior Treatment with Romosozumab for Osteogenesis Imperfecta (clinicaltrialsregister.eu) - P2/3 | N=17 | Not yet recruiting | Sponsor: Amgen Inc.

New P2/3 trial • Genetic Disorders • Pediatrics

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta (clinicaltrials.gov) - P3 | N=32 | Not yet recruiting | Sponsor: Amgen | N=24 ➔ 32

Enrollment change • Genetic Disorders • Pediatrics

Upper arm administration is associated with higher injection site pain with romosozumab: a randomized controlled trial and a self-controlled study. (PubMed, JBMR Plus) - "In conclusion, upper arm injections were associated with greater pain and higher ISR incidence without affecting bone metabolism. Selecting an injection site based on comfort may improve patient experience during romosozumab therapy."

Clinical • Journal • Osteoporosis • Pain • Rheumatology • TRAP

Treatment of osteoporosis in 2026: a sartorial approach. (ISGE 2026) - "In women at high risk of osteoporotic fracture, oral Bisphosphonates or other inhibitors of bone resorption (Denosumab) should be considered. In patients at very high risk of fracture, Anabolic Agents (Teriparatide, Abaloparatide, Romosozumab) followed by an inhibitor of bone resorption are now unanimously accepted as the most appropriate sequential treatment...Percutaneous, transdermal and oral formulations provide a similar benefit to the patient. Initiation of MHT during the first years of menopause ensures a maximal beneficial effect."

Musculoskeletal Diseases • Osteoporosis • Rheumatology

Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture. (PubMed, Clin Exp Rheumatol) - "In post-menopausal women with severe osteoporosis, 12 months of ROMO treatment was associated with a statistically significant reduction in NLR, reflecting a potential modulation of systemic inflammation, though the clinical relevance of this modest shift remains uncertain and warrants further investigation."

Journal • Hematological Disorders • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Current outlook on the use of monoclonal antibody therapies for osteoporosis. (PubMed, Expert Opin Biol Ther) - "The availability of monoclonal antibody therapies impacting on the basic pathways of bone formation ;(romosozumab) and bone resorption (denosumab) has contributed greatly to our ability to manage patients with osteoporosis and fracture risk. Future therapies may direct 'maintenance' therapies to avoid reversal of beneficial effects on monoclonal antibody treatment discontinuation. Other novel therapies being investigated may provide benefits not only to osteoporosis but other diseases associated with aging."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Greater Increase in Bone Strength With Romosozumab vs Teriparatide or Denosumab in Women With Postmenopausal Osteoporosis in Real-world Clinical Setting (AAOS 2026) - "In this real-world BCT study, Romo, TPTD, or DMAb increased vertebral and proximal femoral strength and vBMD in women with PMO. However, the magnitude of improvement varied, with Romo showing greater increase in bone strength and vBMD than TPTD and DMAb."

Clinical • Real-world • Real-world evidence • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Pre-Operative Bone Health in Elective Spine Surgery, From Risk Assessment to Optimization Strategies: A Narrative Review. (PubMed, Global Spine J) - "Specifically, we aimed to: (1) outline risk assessment and diagnostic strategies, including clinical risk factors, laboratory testing, and imaging such as dual-energy x-ray absorptiometry (DEXA) and opportunistic CT-based Hounsfield Unit (HU) analysis; (2) evaluate therapeutic options, emphasizing pharmacologic agents (teriparatide, romosozumab, denosumab, and bisphosphonates) alongside non-pharmacologic measures including nutrition and lifestyle modification; and (3) explore future directions, including therapy duration and economic barriers to wider adoption of newer agents.MethodsThis narrative review synthesizes the current literature on preoperative bone health management in spine surgery. Current evidence supports a multimodal approach combining targeted assessment and timely intervention to mitigate risk of adverse bone-related events following spine surgery.ConclusionsPreoperative bone health optimization is a crucial opportunity to improve long-term outcomes for..."

Journal • Review • Orthopedics • Osteoarthritis • Osteoporosis • Rheumatology

Vertebral Changes Evaluated by Hounsfield Units Following Spinal Fusion Surgery with Concomitant Bone Anabolic Agents' Drugs (AAOS 2026) - "In the present study, we focused on the perioperative period of spinal fusion surgery and divided patients into three groups: osteoporosis treatment-naïve, teriparatide (TPD)-treated, and romosozumab (ROMO)-treated... HU values have been reported to show moderate to strong correlations with BMD and mechanical bone strength, making them a useful method for bone quality assessment. While HU values cannot fully replace DEXA, they offer several advantages in the context of spinal surgery: they can be easily and simultaneously measured from preoperative CT scans. Anabolic agents of osteoporosis have been reported to induce a rapid increase in BMD."

Surgery • Orthopedics • Osteoporosis

Giant Cell Tumor of Bone: Initial Results of Anti-Sclerostin Therapy (AAOS 2026) - "Our results suggest blosozumab (anti-SOST) inhibits GCTB growth when compared to denosumab (RANKL) and exhibits moderate treatment effect compared to control. Differences may exist in the efficacy of anti-SOST treatments, blosozumab and romosozumab, and may stem from variations in antibody isotope (IgG2 vs IgG4) or binding epitope specificity. Further research is required to determine the clinical translatability of these findings but may indicate a role f or anti-SOST treatment in GCTB."

Giant Cell Tumor of Bone • Oncology • Osteoporosis • Osteosarcoma • Solid Tumor • H3-3A